


**Supplemental Figure 1:** A–C. miR-183, miR-96 and miR-182 levels were significantly increased for 5 days after transfection with miR-182, miR-183 and miR-96 mimics. **D.** The miR-182 level was significantly reduced at 5 days after transfection with anti-miR-182. Data are shown as means ± S.E. Student's *t*-test, \*\* = P<0.01.

```
3' gccacacucaagauGGUAACGGUUu 5' mmu-miR-182
|| || || || ||
56:5' ccuacagagaaaacCCUUUGCCAAa 3' Foxo3a

3' ucguuuuuacacgaucACGGUUu 5' mmu-miR-96
|| || || ||
58:5' uacagagaaaacccuuUGCCAAa 3' Foxo3a
```

**Supplemental Figure 2:** The *in silico*-predicted binding site of miR-182 and miR-96 in the 3'-UTR of FOXO3a.



Supplemental Figure 3: FOXO1 and BRCA 1 are not involved in the response of hair cells to cisplatin cytotoxicity. A. Slight increase of FOXO1 mRNA level during the 24h of cisplatin treatment. B. No significant differences in BRCA 1 mRNA level during the 24h of cisplatin treatment. C. Transfection with miR-182 mimics before treatment with cisplatin for 24 h did not inhibit the increase in FOXO1 and BRCA 1 mRNA level. D, E No significant FOXO1 immunofluorescent staining (white arrowheads) was observed in hair cell nuclei irrespective of whether they were treated with cisplatin alone or transfected with miR-182 mimics or control oligos. F. After treatment with cisplatin for 24 h, Western blot analysis showed no significant difference in the FOXO1 protein level compared to the control group. G. After transfection with miR-182 mimics followed by treatment with cisplatin for 24 h, there

was no significant difference in the FOXO1 protein level between the miR-182 OE group and control group. Data are shown as means ± S.E. Student's *E*test.